Bioexpert network have evalutionized of ArtGen

REPORT
The BioExpert Network is an exclusive network of
industry experts in the sectors of life science and
investment. Members evaluate funding proposals
for innovative research and development projects.
2018 - BioExpert Network

This report includes all the comments and questions from the experts,
without editing the content or correcting spelling mistakes.
For the evaluation of the company, the experts have had access to
the pitch deck of the company and to the responses and comments
that the company has been offering through the discussion forum.
Only proposals which receive the most positive responses, in terms of novel
concepts, scientific validity and financial accuracy, successfully progress to
funding campaign stage on the Capital Cell equity crowdfunding platform.
The pitch deck of the company includes basic information about the
company, specifically about:
• The team
• The product, technology or science
• The business model
• The innovation
• The pre-money valuation of the company

ArtGen
Team 9
Science 8
Innovation 8
Business Potential 8
7.6
Overall Grade
Each expert has given an overall grade to the whole
project following the question “How would you rate
the project’s chances of success, overall?“.
Pre-money valuation
3 Experts said:It is reasonable
2 Experts said:Information not provided
1 Experts said:Not my area of expertise
1 Experts said:Between 40% and 60% too high

This company has been evaluated by 7 experts
Team
The experts have answered to the question: How would you rate the expertise of the team?
8
Raul Rincon - Experience in: Biotech Cancer therapeutics Drug Discovery Oncology Therapeutics
Artgen team expertise exhibits clinical and research experience to be trusted.
0
8
Undisclosable Expert - Experience in: Cancer therapeutics Immunology Oncology Therapeutics antibodies
cell therapy peptides vaccines
0
10
Arturo López - Experience in: Biotechnology Business strategy Capital raising Diagnostics Drug discovery
Medical devices Pharmaceuticals Startups Technology transfer
The team expertise is strong, containing all the di erent and speci c skills for the type of
development needed for this type of product
0

8
Undisclosable Expert - Experience in: Agritech Bioinformatics Biotech Cancer therapeutics Diagnostics
Digital Health Drug Discovery Food tech Genomics Health tech Immunology Medical Device Medicine Nanotechnology
Therapeutics Veterinary Health Business strategy Market access Startups Technology transfer
Team has experience in Russia and US with medical use ,experience with business potential in
US
0
9
Undisclosable Expert - Experience in: Clinical trials Diagnostics Immunology Medicine
Personalised medicine Predictive medicine Therapeutics general (internal) medicine infectious diseases
preventive medicine
0
8
Undisclosable Expert - Experience in: Funding sources Cancer therapeutics Diagnostics Drug Delivery
Genomics Health tech Medical Device Nanotechnology Neurosciences IP & Licensing Startups Technology transfer
0

Science
The experts have answered to the question: How would you rate the scienti c viability of the
company?
9
This direct gene therapy proposed seems to be clinically e ective. I predict a huge potential to
treat PAD patients.
0
9
0
9
Daniel Cravo - Experience in: Biotech Clinical trials Drug Delivery Drug Discovery chemical engineering other
the idea of improving an existing active treatment is really good. Nevertheless some areas
need to be clari ed (such as safety, side e ects, active dose, IP) in order to choose to invest or
not.
0
9

This is a clinical project based on the improvement of a already tested gene therapy drug. The
potential of being successful is very high
0
8
>2000 patients injected in Russia – Russian drug Neovasculgen
0
6
preventive medicine
0
7
0

Innovation
The experts have answered to the question: How would you rate the degree of innovation of the
company?
9
This kind of novel treatments could improve current surgeries outcomes.
0
7
0
7
Improving the low half life of Neovasculagen is really a big shift for a better clinical activity. Now
this has to be shown during the clinical trials.
Also, ART-101 is a new compound (even if it is close to Neovasculagen), so I don’t expect the
same safety and e cacy pro le.
0
8

Innovation is coming from changing/improving a product that already works… and looking for
approval in a large patient market. In this case both things a very good option.
0
8
from website – http://www.artgentx.com
ART-101 – injectable supercoiled DNA plasmid coding for Vascular Endothelial Growth Factor
(VEGF)
Induce blood vessel creation and restore blood ow to the limb, leading to a reduction in pain
and risks of cardiovascular events in stages II and III of PAD (peripheral arterial disease).
Stimulates angiogenesis in surrounding tissue via the VEGF-pathway
Designed to treat PAD (Stages 2/3) and arrest/reverse disease progression
Based on Russian drug Neovasculgen, used on 2000 patients
0
9
preventive medicine
0
8

Business Potential
The experts have answered to the question: How would you rate the business potential of the
company?
9
As a real clinical alternative to improve PAD patients outcome, ArtGen new therapy must
achieve a great business potential after clinical trials were nished.
0
8
The present project presents a very broad market of action. The results achieved to date, and
future actions, indicate a high business potential.
0
8
The number of patient by 2020 is attractive, and the treatment cost high enough to ensure
decent revenue.
Two questions remain: the evolution of morbidity by 2050 and what is the expected market
share for such a treatment ?
0

9
Numbers of people potentially having PAD is high… and growing in developed countries like US
0
8
US patients – 18 million with PAD
7 million or more people stage II or III PAD /4.3 billion dollar
$7000 for 2 injections
instead of surgical intervention or stents and angioplasty
0
9
preventive medicine
PAD is a prevalent disease and current therapeutic options are not great, especially in diabetic
patients.
0
7

it’s improvement of a therapy in use
0

Pre-money valuation
The experts have answered to the question: How reasonable is the pre-money valuation?
It is
reasonable
I assess as reasonable the pre-evaluation costs of ArtGen development strategy considering
the di erent clinical trial stages they have to performance.
0
It is
reasonable
The valuation that is made in the project ts with the (broad) market of action, and therefore I
consider it reasonable.
0
Information
not provided
the expected market share for this treatment and the current market share from competitors
will help forecast a valuation.
0

It is
reasonable
Budget estimation for clinical drug validation in a high prevalent disease and for a gene therapy
format is going to need a lot of patients to the achievement of relevant and consistent results
in order to get regulatory approval. Spent is going to be high.
0
Between 40%
and 60% too
high
Drug is developed, cost of production should decrease, clinical studies for FDA approval are
costly however other pharma request less monies to do similar testing
0
Not my area
of expertise
preventive medicine
0

Information
not provided
not provided
0

Overall grade
Each expert has answered to the question: What are your general thoughts about this proposal?
8
ArtGen’s new gene-therapy proposal has a huge potential to become a true clinical alternative
to be validated and incorporated to PAD therapies. This clinical innovation could be very
interesting to biotech investors and CV disease experts and it would be a real progress in these
treatments.
0
7
The treatment proposed in the present project, improves the actions of other drugs, and
therefore has a certain innovative character. Moreover, and in view of the previous results
presented with nearly 2,000 patients, the increase in the improvement of the quality of life is a
very important aspect of the project. My only doubt is the e ect of constant (CMV regulated)
high expression of VEGF in the a ected area.
0
7
All my thoughts are driven by the non con dential information provided.
The company is not moving in unknown land. The Neovasculagen data are very useful to give
good hope of success. Nevertheless, ART-101 is not Neovasculagen. So there is some
uncertainty about the safety and e cacy pro le.
0

8
This is not a typical drug development project… the drug already shown e cacy and no toxicity
in its rst version and now the developers want to test the slightly changed second version… a
priori not a lot of issues should appear although FDA will be looking during all the phases with
strong detail.
0
8
Useful drug if approved in US with larger test group
0
8
preventive medicine
The clinical data about the e cacy of Neovasculagen and the in vitro data of ART101 are
promising. Although the product is at an early stage and the investment risk is high, the team
looks strong and capable of developing ART101 to Stage II-III.
0

7
I think that the is lower than in other therapy projects
0

Other Comments
If you want to invest, be sure to be fully in agreement with what the company promises. Advice
can be helpful.
0
Although it is a mature project, detailed scienti c data is not shown in order to have an idea of
how the drug is working (mechanism of action) in its rst version… For this type of pathology
the run is still large with long clinical trials to be assumed although part of the risks considered
during a drug development should be out.
0

Revolutionise science with your knowledge
www.bioexpertnetwork.com

Bioexpert network have evalutionized of ArtGen

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Bioexpert network have evalutionized of ArtGen

Similar to Bioexpert network have evalutionized of ArtGen (20)

More from Boris Maizel

More from Boris Maizel (17)

Recently uploaded

Recently uploaded (20)

Bioexpert network have evalutionized of ArtGen